With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

GLP-1s have quickly ... potential of GLP-1 therapy. To achieve the best results, these programmes must focus on breaking down the common barriers that make weight loss so challenging, including ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...